Vivos Therapeutics (VVOS) Provides Update on Revenue Recognition Review
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Vivos Therapeutics Provides Update on Revenue Recognition Review
November 22, 2022 7:30 AM ESTDetailed Analysis Finds Minimal Impact on Prior Financial Results;No Previously Reported Revenue to be Lost
Previously Reported First Quarter 2022 Revenue Expected to Increase Approximately $200,000; No Need to Restate Prior Year Financial Statements
Restated First Quarter 2022 Results to be Filed Shortly;Second and Third Quarter 2022 Financial Results Expected By Year End
HIGHLANDS RANCH, Colo., Nov. 22, 2022 (GLOBE NEWSWIRE) --... More
